Radiopharm Theranostics (NASDAQ:RADX) Earns “Buy” Rating from B. Riley

Radiopharm Theranostics (NASDAQ:RADX)‘s stock had its “buy” rating reissued by equities research analysts at B. Riley in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 target price on the stock, up from their prior target price of $13.00. B. Riley’s target price would indicate a potential upside of 164.90% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Radiopharm Theranostics currently has a consensus rating of “Buy” and a consensus price target of $15.33.

Radiopharm Theranostics Stock Down 43.2%

RADX stock traded down $4.59 during trading on Tuesday, reaching $6.04. 1,468,996 shares of the stock were exchanged, compared to its average volume of 239,276. Radiopharm Theranostics has a twelve month low of $3.50 and a twelve month high of $16.25. The stock has a 50 day simple moving average of $5.33 and a 200-day simple moving average of $5.24.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,000 shares of the company’s stock after purchasing an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent filing with the SEC.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.